Sanofi position in INBX
INHIBRX BIOSCIENCES INC · Health Care
Sanofi reported holding 1,157,926 shares of INBX (INHIBRX BIOSCIENCES INC) in its Q3 2026 13F filing — a position valued at US$115.9M, representing 18.40% of its reported portfolio and ranking #2 among its reported holdings. Sanofi has disclosed INBX holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
Last updated: 2026-11-05 · Source: SEC EDGAR Form 13F-HR
How Sanofi's INBX position evolved
Sanofi first disclosed a stake in INBX in Q4 2024 at 1,157,926 shares (US$17.8M). The position peaked in Q3 2026 at 1,157,926 shares, worth US$115.9M. Across 8 filings, Sanofi held the position steady without any share-count change. The most recent filing (Q3 2026) shows 1,157,926 shares valued at US$115.9M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 1.16M | $17.83M | New |
| Q1 2025 | 1.16M | $16.20M | Hold |
| Q2 2025 | 1.16M | $16.52M | Hold |
| Q3 2025 | 1.16M | $39.00M | Hold |
| Q4 2025 | 1.16M | $91.48M | Hold |
| Q1 2026 | 1.16M | $77.85M | Hold |
| Q2 2026 | 1.16M | $109.71M | Hold |
| Q3 2026 | 1.16M | $115.89M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About INBX and 13F data
INBX (INHIBRX BIOSCIENCES INC) is a Health Care company. 43 other funds we track also report a position in INBX — the largest reported positions include PERCEPTIVE ADVISORS LLC (US$123.0M), Schonfeld Strategic Advisors LLC (US$66.1M), PFM Health Sciences, LP (US$29.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding INBX
- PERCEPTIVE ADVISORS LLC 1.30M sh · $122.96M · Q2 2026
- Schonfeld Strategic Advisors LLC 697.59K sh · $66.10M · Q2 2026
- PFM Health Sciences, LP 308.38K sh · $29.22M · Q2 2026
- Sofinnova Investments, Inc. 303.10K sh · $28.72M · Q2 2026
- Parkman Healthcare Partners LLC 256.95K sh · $24.35M · Q2 2026
- First Turn Management, LLC 164.78K sh · $15.61M · Q2 2026
- Western Standard LLC 47.00K sh · $4.45M · Q2 2026
FAQ
How long has Sanofi held INBX?
Sanofi has disclosed INBX holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
What is Sanofi's current position in INBX?
As of Q3 2026, Sanofi holds 1.16M shares of INBX (INHIBRX BIOSCIENCES INC), valued at $115.89M, representing 18.40% of its reported portfolio and ranking #2.
Has Sanofi been buying or selling INBX?
In the latest 13F filing (Q3 2026), Sanofi held unchanged its position in INBX. The position peaked in Q3 2026 at 1.16M shares.
Which other funds hold INBX?
Other major institutional holders of INBX include PERCEPTIVE ADVISORS LLC, Schonfeld Strategic Advisors LLC, PFM Health Sciences, LP, among 43 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.